219 related articles for article (PubMed ID: 8964086)
1. Generation of antigenic peptides by lymphocyte granule serine proteases (granzymes).
Carter CR; Sayers TJ; Wiltrout RH; Turcovski-Corrales SM; Taub DD
Cell Immunol; 1996 Sep; 172(2):235-45. PubMed ID: 8964086
[TBL] [Abstract][Full Text] [Related]
2. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
Lipford GB; Hoffman M; Wagner H; Heeg K
J Immunol; 1993 Feb; 150(4):1212-22. PubMed ID: 7679422
[TBL] [Abstract][Full Text] [Related]
3. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
[TBL] [Abstract][Full Text] [Related]
4. Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway.
Garg N; Nunes MP; Tarleton RL
J Immunol; 1997 Apr; 158(7):3293-302. PubMed ID: 9120286
[TBL] [Abstract][Full Text] [Related]
5. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
Ma H; Kapp JA
Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
[TBL] [Abstract][Full Text] [Related]
6. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
7. Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides.
Hosken NA; Bevan MJ; Carbone FR
J Immunol; 1989 Feb; 142(4):1079-83. PubMed ID: 2492575
[TBL] [Abstract][Full Text] [Related]
8. Injection of detergent-denatured ovalbumin primes murine class I-restricted cytotoxic T cells in vivo.
Schirmbeck R; Böhm W; Reimann J
Eur J Immunol; 1994 Sep; 24(9):2068-72. PubMed ID: 8088327
[TBL] [Abstract][Full Text] [Related]
9. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses.
Collins DS; Findlay K; Harding CV
J Immunol; 1992 Jun; 148(11):3336-41. PubMed ID: 1588035
[TBL] [Abstract][Full Text] [Related]
10. Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells.
Serwold T; Shastri N
J Immunol; 1999 Apr; 162(8):4712-9. PubMed ID: 10202012
[TBL] [Abstract][Full Text] [Related]
11. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
Newman MJ; Wu JY; Gardner BH; Munroe KJ; Leombruno D; Recchia J; Kensil CR; Coughlin RT
J Immunol; 1992 Apr; 148(8):2357-62. PubMed ID: 1373166
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CPP32-like proteases prevents granzyme B- and Fas-, but not granzyme A-based cytotoxicity exerted by CTL clones.
Anel A; Gamen S; Alava MA; Schmitt-Verhulst AM; Piñeiro A; Naval J
J Immunol; 1997 Mar; 158(5):1999-2006. PubMed ID: 9036942
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide.
Heeg K; Kuon W; Wagner H
Eur J Immunol; 1991 Jun; 21(6):1523-7. PubMed ID: 1904363
[TBL] [Abstract][Full Text] [Related]
14. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
15. Chymase-directed serine protease inhibitor that reacts with a single 30-kDa granzyme and blocks NK-mediated cytotoxicity.
Woodard SL; Jackson DS; Abuelyaman AS; Powers JC; Winkler U; Hudig D
J Immunol; 1994 Dec; 153(11):5016-25. PubMed ID: 7963562
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes.
Brown GR; McGuire MJ; Thiele DL
J Immunol; 1993 Jun; 150(11):4733-42. PubMed ID: 8496587
[TBL] [Abstract][Full Text] [Related]
17. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
Rock KL; Fleischacker C; Gamble S
J Immunol; 1993 Feb; 150(4):1244-52. PubMed ID: 8381832
[TBL] [Abstract][Full Text] [Related]
18. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
19. Immunopurification of functional Asp-ase (natural killer cell granzyme B) using a monoclonal antibody.
Trapani JA; Browne KA; Dawson M; Smyth MJ
Biochem Biophys Res Commun; 1993 Sep; 195(2):910-20. PubMed ID: 8373425
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
